

Press release

Ethypharm and CTRS sign a partnership agreement to register and commercialise Orphacol® in China

St-Cloud and Boulogne-Billancourt, France - November 10, 2020 – Ethypharm and Laboratoires CTRS announced today that they have entered into an exclusive agreement for the registration and commercialisation in the People’s Republic of China of the orphan medicine Orphacol® indicated for the treatment of patients with rare inborn errors in primary bile acid synthesis.

Under the agreement, CTRS has granted Ethypharm the exclusive rights for Orphacol® in the People’s Republic of China. Ethypharm and CTRS will jointly fund and undertake all the necessary requirements to bring Orphacol® to market in China. After registration, Ethypharm will be responsible for the distribution, marketing and sale of the products in that territory.

Orphacol® (cholic acid) is already approved in Europe where it benefits from an orphan drug status. It is indicated for two rare inborn errors of primary bile acid synthesis. The innovation brought by Orphacol® to patients has been highly recognised by the scientific community.

Successfully operating in the fast-changing Chinese environment for over 20 years, Ethypharm has a fully integrated subsidiary located in Shanghai. This affiliate is a partner of choice for companies that wish to bring to Chinese patients their already internationally marketed rare disease or orphan medicines.

“This partnership with CTRS represents an important milestone for Ethypharm in the construction of our rare disease franchise in China. Orphacol® is a highly innovative life-saving product which fulfils unmet medical need. We are proud to participate in its success and make this medicine available to the affected patients in China” said Bertrand DELUARD – President & CEO of Ethypharm.

“We are very pleased to enter into this exclusive license agreement with Ethypharm based on its deep insight and unique capabilities in China, which make us highly confident that the Chinese patients suffering of bile acid synthesis disorders will quickly have access to Orphacol®” added Antoine FERRY, CEO of Laboratoires CTRS.

About the Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two therapeutic areas: The Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China.

Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

For more information on Ethypharm, visit <http://www.ethypharm.com> and follow us on [LinkedIn](#).

About Laboratoires CTRS

Laboratoires CTRS is a pharmaceutical company based in France with a strong and growing international presence in orphan and ultra-orphan disorders. CTRS has successfully established public-private partnerships and collaborations with leading research groups with predominant focus on genetic disorders and cancer.

CTRS has a staff of 20+ employees and a network of long-term contractors/commercial partners around the world. For more information about us, please go to www.ctrs.fr and follow us on [LinkedIn](#).

About Orphacol®

Orphacol® (cholic acid) is an approved treatment for inborn errors in primary bile acid synthesis due to 3 β -hydroxy- Δ^5 -C₂₇-steroid oxidoreductase deficiency or Δ^4 -3-oxosteroid-5 β -reductase deficiency. Orphacol® has a centralised marketing authorisation, valid for all markets of the EU, Norway and Iceland. The product also enjoys orphan drug market exclusivity. Orphacol® is a life-saving treatment which has obtained national and international awards such as “Prix Galien” and “International Prix Galien”. The product also obtained the highest recognition from Prescrire (an independent medical journal in France).

Press contact

Avril PONNELLE / presse@ethypharm.com / + 33 (0)1 41 12 17 20

Laetitia EVAÏN / levain@ctrs.fr / +33 (0)1 41 22 09 70